Go behind the scenes with Scrip, as expert analysts examine the machinations of Roche’s acquisition of Spark Therapeutics, Inc. Find out in this informative article how Roche secured the deal in the face of strong competition from three other rival companies.
Author: Kevin Grogan
Published: 08 March 2019
Number of pages:2
Examine the behind-the-scenes action regarding Roche’s acquisition of Spark Therapeutics Inc. in this insightful article from Scrip. Analysts dissect a Securities and Exchange (SEC) commission filing by Spark to paint a picture of the skillful negotiating tactics employed by Spark CEO Jeff Marrazzo. See how his plan resulted in successfully driving up Spark’s per share price by more than 60% over its first offer, and how Roche ultimately secured the acquisition. Get the details on this $4.8b deal here.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.